These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20431446)

  • 21. Fluid retention in cirrhosis: pathophysiology and management.
    Kashani A; Landaverde C; Medici V; Rossaro L
    QJM; 2008 Feb; 101(2):71-85. PubMed ID: 18184668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
    Gentilini P; Laffi G; La Villa G; Raggi VC
    Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in hepatorenal syndrome.
    Arroyo V; Torre A; Guevara M
    Trop Gastroenterol; 2005; 26(1):13-20. PubMed ID: 15974232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
    Moreau R; Lebrec D
    Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ascites in liver diseases.
    Gentilini P; Laffi G
    Ann Ital Med Int; 1991; 6(1 Pt 2):148-55. PubMed ID: 1742150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatorenal syndrome in patients with liver cirrhosis].
    Zaza S; Bonny O; Liaudet L
    Nephrol Ther; 2005 Jul; 1(3):174-82. PubMed ID: 16895684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organ interactions in the hepatorenal syndrome.
    Neuschwander-Tetri BA
    New Horiz; 1994 Nov; 2(4):527-44. PubMed ID: 7804802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy insight: Management of hepatorenal syndrome.
    Cárdenas A; Ginès P
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):338-48. PubMed ID: 16741553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?
    Møller S; Henriksen JH
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():31-41; discussion 42-3. PubMed ID: 15335398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy of hepatorenal syndrome].
    Walter E
    Praxis (Bern 1994); 1997 Jan; 86(4):102-3. PubMed ID: 9064719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Splanchnic and systemic vasodilatation: the patient.
    Tsai MH
    J Clin Gastroenterol; 2007; 41 Suppl 3():S266-71. PubMed ID: 17975476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatorenal syndrome: pathophysiology and treatment.
    Pandey CK; Singh N; Kumar V; Agarwal A; Baronia AK; Gaur A; Singh PK; Singh S
    J Assoc Physicians India; 2002 Jun; 50():819-25. PubMed ID: 12240852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New challenge of hepatorenal syndrome: prevention and treatment.
    Wong F; Blendis L
    Hepatology; 2001 Dec; 34(6):1242-51. PubMed ID: 11732014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnostics and therapy of hepatorenal syndrome. Recommendations of of the working group on portal hypertension of the Czech Hepatology Society and the J. E. Purkinje Czech Medical Society].
    Brůha R; Skupiny C; Balihar K; Drastich P; Hůlek P; Lata J; Petrtýl J; Procházka V; Spicák J; Vanásek T; Volfová M; Zdenek P; ;
    Vnitr Lek; 2006 Jun; 52(6):649-50. PubMed ID: 16871772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy.
    Arroyo V
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():49-54; discussion 55-6. PubMed ID: 15335402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Liver cirrhosis and cardiovascular system].
    Ponte E; Cafagna D
    Minerva Med; 1996 Jun; 87(6):299-310. PubMed ID: 8700359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.
    Arroyo V; Ginès P; Gerbes AL; Dudley FJ; Gentilini P; Laffi G; Reynolds TB; Ring-Larsen H; Schölmerich J
    Hepatology; 1996 Jan; 23(1):164-76. PubMed ID: 8550036
    [No Abstract]   [Full Text] [Related]  

  • 39. Pathogenesis and treatment of hepatorenal syndrome.
    Arroyo V; Fernandez J; Ginès P
    Semin Liver Dis; 2008 Feb; 28(1):81-95. PubMed ID: 18293279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.